Topic:

Partnering

Latest Headlines

Latest Headlines

Bristol-Myers to collaborate with Calibr on fibrosis drugs

Bristol-Myers Squibb is turning to the California Institute for Biomedical Research (Calibr) in San Diego for new fibrosis drug candidates.

Evotec teams up with Ohio State on a new cancer drug

German contract researcher Evotec has paired off with Ohio State to help the school develop an in-house cancer prospect, lending its technology and expertise.

Amgen, Kite partner their hot CAR-T and IO tech in blockbuster cancer pact

Amgen has found a CAR-T development partner. The Big Biotech is partnering up with Kite Pharma on new drugs that use Kite's chimeric antigen receptor tech, which turns T cells in the immune system into cancer-cell attack weapons. And they're both putting up some major milestone cash to fuel the work.

J&J inks an $835M RNA deal to develop autoimmune drugs with Isis

You can now count Johnson & Johnson among the roster of big companies to ally itself with Isis Pharmaceuticals' R&D group. J&J has stepped up with an $835 million pact to develop new drugs for autoimmune diseases of the gastrointestinal tract with the RNA specialists at Isis.

PPD bets on Japan with new joint venture

PPD has signed a deal with service provider Shin Nippon Biomedical Laboratories to collaborate in Japan, pooling resources in a joint venture designed to tap the growing market for clinical research there.

Teva hands over $27M, cancer drug rights to OncoGenex in Phase III divorce

Eight months after OncoGenex Pharmaceuticals and Teva acknowledged that their experimental cancer drug custirsen had flopped in a Phase III prostate cancer study, the big Israeli pharma company has executed a strategic retreat from their partnership. Teva is handing over $27 million to OncoGenex to complete the divorce and is walking away from a deal that included $60 million in upfront costs back in 2009.

Study finds doing mock injections helps patients self-administer drugs, biologics without mistakes

Two recent surveys covered by FierceDrugDelivery have shown that the vast majority of patients don't use their drug delivery devices properly. Device training specialist Noble says improved patient education is the key.

Medivation buys into PD-1, picking up where Teva left off

The prostate cancer experts at Medivation are getting into the hot field of checkpoint inhibitors for cancer, agreeing to pay Israel's CureTech as much as $335 million for the full rights to a promising Phase II asset.

Ariad flips Iclusig's Asian rights to Otsuka for $77.5M-plus

Embattled biotech Ariad Pharmaceuticals has signed a deal with Japan's Otsuka to trade the Asian rights to its top cancer drug in exchange for $77.5 million and the promise of more down the line.

Astellas adds to deal spree with expanded $675M-plus Cytokinetics pact

Astellas has capped a string of new drug development deals by upping the ante on its pact with South San Francisco-based Cytokinetics. After handing over a $40 million upfront fee for their original 2013 deal, Astellas has come back with $75 million more in near-term financing and more than $600 million in milestones on the table.